Eledon Pharmaceuticals (ELDN) News Today $1.14 -0.01 (-0.87%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$1.12▼$1.1650-Day Range$1.12▼$1.6952-Week Range$1.07▼$3.70Volume38,488 shsAverage Volume58,054 shsMarket Capitalization$27.59 millionP/E RatioN/ADividend YieldN/APrice Target$10.67 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conferencefinance.yahoo.com - November 29 at 7:23 PMEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Resultsfinanznachrichten.de - November 10 at 7:37 AMEledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?msn.com - November 9 at 4:28 PMEledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - November 9 at 4:28 PMEledon Pharmaceuticals to Present at Jefferies London Healthcare Conferencefinance.yahoo.com - November 8 at 7:22 PMPromising Results and Buy Rating for Eledon Pharmaceuticals: Tegoprubart’s Potential in Kidney Transplant Therapymarkets.businessinsider.com - November 6 at 6:54 PMPromising Phase Ib Study Results Bolster Buy Rating for Eledon Pharmaceuticals: An Analysis by Rami Katkhudamarkets.businessinsider.com - November 4 at 8:55 AMEledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantationfinance.yahoo.com - November 2 at 1:53 PMHC Wainwright & Co. Maintains Eledon Pharmaceuticals (ELDN) Buy Recommendationmsn.com - October 24 at 7:00 PMEledon Pharmaceuticals appoints Eliezer Katz as CMOmsn.com - October 23 at 9:00 AMEledon Pharmaceuticals Appoints Eliezer Katz As Chief Medical Officermarkets.businessinsider.com - October 23 at 9:00 AMEledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officerfinance.yahoo.com - October 23 at 9:00 AMEledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meetingfinance.yahoo.com - October 13 at 9:59 AMEledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directorsfinance.yahoo.com - October 2 at 8:12 AMNoble Capital Markets Initiates Coverage of Eledon Pharmaceuticals (ELDN) with Outperform Recommendationnasdaq.com - September 28 at 12:26 AMPromising Clinical Trials and Future Projections Bolster Buy Rating for Eledon Pharmaceuticalsmarkets.businessinsider.com - September 27 at 9:24 AMEledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Humanfinance.yahoo.com - September 25 at 7:58 AMEledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conferencefinance.yahoo.com - September 20 at 8:16 PMEledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primatesfinance.yahoo.com - September 6 at 11:52 AMEledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantationfinance.yahoo.com - September 5 at 11:44 AMCantor Fitzgerald Reiterates Eledon Pharmaceuticals (ELDN) Overweight Recommendationmsn.com - August 22 at 4:40 PMEledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantationfinance.yahoo.com - August 16 at 1:50 PMEledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - August 10 at 8:22 AMIs Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - July 17 at 2:09 PMAmerigo Reports Q2-2023 Production Results and Provides MVC Operational Updatefinance.yahoo.com - July 12 at 8:01 AMSVB Securities Reaffirms Their Buy Rating on Eledon Pharmaceuticals (ELDN)markets.businessinsider.com - June 3 at 10:41 AMEledon Pharmaceuticals to Present at Jefferies Healthcare Conferencefinance.yahoo.com - June 2 at 9:25 AMEledon Pharmaceuticals GAAP EPS of -$0.75 misses by $0.11msn.com - May 11 at 7:45 PMEledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - May 11 at 7:45 PMEledon Pharmaceuticals: Disrupting The Kidney Transplantation Landscapemsn.com - May 10 at 6:41 PMEledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023finance.yahoo.com - May 4 at 5:02 PMEledon stock rises ~10% after up to $185M financingmsn.com - May 1 at 10:58 AMEledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trialsfinance.yahoo.com - May 1 at 10:58 AMEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - April 6 at 12:39 AMEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Resultsfinanznachrichten.de - April 1 at 1:56 AMAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Eledon Pharmaceuticals (ELDN)markets.businessinsider.com - March 31 at 10:52 AMEledon tegoprubart shows promise in kidney transplant patients in phase 1b trialmsn.com - March 31 at 10:52 AMEledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrologyfinance.yahoo.com - March 31 at 10:52 AMEledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Resultsfinance.yahoo.com - March 30 at 6:31 PMEledon Pharmaceuticals's Earnings: A Previewmsn.com - March 29 at 5:28 PMAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Eledon Pharmaceuticals (ELDN) and Celcuity (CELC)markets.businessinsider.com - March 28 at 8:30 AMEledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023finance.yahoo.com - March 23 at 5:43 PMEledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023finance.yahoo.com - March 23 at 12:42 PMEledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conferencefinance.yahoo.com - February 8 at 6:24 PMeGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studiesfinance.yahoo.com - January 9 at 9:17 AMEledon Pharmaceuticals Provides Business and Pipeline Updatesfinance.yahoo.com - January 9 at 9:17 AMC-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring Systemfinance.yahoo.com - December 21 at 7:47 PMEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Resultsfinanznachrichten.de - December 1 at 3:38 PMEledon Pharmaceuticals, Inc. (ELDN) Q3 2022 Earnings Call Transcriptseekingalpha.com - November 15 at 4:40 AMEledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Resultsfinance.yahoo.com - November 15 at 4:40 AM Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address ELDN Media Mentions By Week ELDN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELDN News Sentiment▼0.890.77▲Average Medical News Sentiment ELDN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELDN Articles This Week▼31▲ELDN Articles Average Week Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KRRO News Today EFTR News Today UBX News Today XLO News Today RGLS News Today SLS News Today GANX News Today SLGL News Today CLRB News Today RZLT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:ELDN) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.